Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOX-CRT-01 in Unresectable Locally Advanced Esophageal Cancer
NCT03991104Phase 2Withdrawn
- Sponsor
- Zhejiang Provincial People's Hospital
- Start
- May 2019
- Primary completion
- Dec 2021
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin and tegafur in esophageal cancer, sponsored by Zhejiang Provincial People's Hospital. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 1 month and Response rate at 1 month. Planned start May 2019; status: withdrawn.
02
Drugs
oxaliplatintegafur
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT03991104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03991104.